化疗加纳武利尤单抗作为不可切除的晚期或复发性胃癌的一线治疗后的转换手术以及使用 Gustave Roussy 免疫评分的生物标志物研究：一项多中心研究。
Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score: A Multicenter Study.
发表日期：2024 Sep 03
作者：
Nobuhiro Nakazawa, Makoto Sohda, Nobuhiro Hosoi, Takayoshi Watanabe, Yuji Kumakura, Toshiki Yamashita, Naritaka Tanaka, Kana Saito, Akiharu Kimura, Kengo Kasuga, Kenji Nakazato, Daisuke Yoshinari, Hisashi Shimizu, Yasunari Ubukata, Hisashi Hosaka, Akihiko Sano, Makoto Sakai, Hiroomi Ogawa, Ken Shirabe, Hiroshi Saeki
来源：
ANNALS OF SURGICAL ONCOLOGY
摘要：
关于化疗加纳武利尤单抗作为不可切除的晚期或复发性胃癌（GC）患者一线治疗的转化手术（CS）的报道很少。这项多中心研究的目的是分析化疗加纳武单抗作为一线治疗后 CS 的真实数据，并确定预测性生物标志物。这项多中心研究包括 104 名接受化疗加纳武单抗作为主要治疗的患者，这些患者来自 12 名患者，接受化疗加纳武单抗作为主要治疗。机构。我们调查分析了有无CS的患者特征和血液检测数据、Gustave Roussy免疫评分（GRIm-s）与CS之间的关系以及CS病例的特征。 12例患者（11.5%）进行了CS ）。接受 CS 的患者东部肿瘤合作组表现状态 (ECOG-PS) 明显更好 (p < 0.0001)。没有高危 GRIm-s 的 CS 病例 (0%)，但有 22 例非 CS 病例 (23.9%)。没有高危 GRIm-s 病例转为 CS。 50.0%的病例进行了微创手术，所有病例均实现R0切除，仅1例术后出现尿潴留（II级），术后短期疗效良好。术后复发 2 例（16.7%），均为 1b 级。本研究中化疗加纳武利尤单抗作为 GC 一线治疗后的 CS 术后短期结果可以接受。接受 CS 的患者中没有出现高风险 GRIm-s 病例，这表明 GRIm-s 可能是 CS 的预测因子。© 2024。外科肿瘤学会。
There are few reports on conversion surgery (CS) after chemotherapy plus nivolumab as a first-line treatment in patients with unresectable advanced or recurrent gastric cancer (GC). This multicenter study was conducted to analyze real-world data on CS after chemotherapy plus nivolumab as a first-line treatment and to identify predictive biomarkers.This multicenter study included 104 patients who received chemotherapy plus nivolumab as primary treatment for unresectable advanced recurrent GC from 12 institutes. We investigated and analyzed patient characteristics and blood test data in the presence or absence of CS, the relationship between the Gustave Roussy Immune Score (GRIm-s) and CS, and the characteristics of CS cases.CS was performed in 12 patients (11.5%). Eastern Cooperative Oncology Group Performance Status (ECOG-PS) was significantly better in patients who underwent CS (p < 0.0001). There were no CS cases with high-risk GRIm-s (0%), however there were 22 non-CS cases (23.9%). No high-risk GRIm-s cases were converted to CS. Minimally invasive surgery was performed in 50.0% of the cases, with R0 resection in all cases and only one case of urinary retention (Grade II) as a postoperative complication, indicating a good postoperative short-term outcome. There were two cases of postoperative recurrence (16.7%), both of which were grade 1b.The short-term postoperative results of CS after chemotherapy plus nivolumab as the first-line treatment for GC were acceptable in this study. There were no high-risk GRIm-s cases among those who underwent CS, suggesting that the GRIm-s may be a predictor of CS.© 2024. Society of Surgical Oncology.